References
- Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol 2014;49:1–6.
- Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol 2008;155:1085–92.
- Navas-Lopez VM, Blasco-Alonso J, Giron-Fernandez-Crehuet F, Serrano-Nieto MJ, Sierra-Salinas C. Efficacy and safety of adalimumab in the treatment of Crohn s disease in children. Rev Esp Enferm Dig 2013;105:579–84.
- Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2634–43.
- Yousefi A, Shafieyoun A, Fallahi G, Rezaei N. Probiotics on fecal calprotectin of cystic fibrosis. Turk J Pediatr 2014;56:333.
- Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring) 2013;21:E607–15.
- Jost T, Lacroix C, Braegger C, Chassard C. Stability of the maternal gut microbiota during late pregnancy and early lactation. Curr Microbiol 2014;68:419–27.
- Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2014; Epub ahead of print.
- Agilli M, Aydin I, Aydin FN. Fecal calprotectin levels in patients with cystic fibrosis. Turk J Pediatr 2014;56:332.
- Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162–9.